Table 1 Participant characteristics.

From: Validating virtual administration of neuropsychological testing in Parkinson disease: a pilot study

Characteristic

N

Value (Mean (SD)) or percentage

Demographics

 Sex (% male)

35

62.9

 Age (years)

35

69.1 (7.8)

 Education (years)

35

16.7 (2.1)

 Race (% white)

35

100

 PD duration (years)

35

10.5 (5.3)

Clinical assessments

 Total LEDDa (mg/day)

35

906.5 (570.8)

 UPDRSb III

35

23.3 (11.7)

 Geriatric depression scale—15 Item

35

2.6 (2.3)

 Hoehn and Yahr stage

35

2.4 (0.7)

Cognitive assessments (in-person results)

 DRS-2c

35

136.1 (5.9)

 MoCAd

35

26.7 (2.6)

 Clock draw test

35

5.2 (1.1)

 Boston naming test

35

57.5 (3.2)

 Judgment of line orientation

35

23.3 (4.3)

 Trails A

35

42.6 (17.0)

 Trails B

35

99.5 (57.8)

 Symbol digit modalities test

35

33.9 (12.0)

 HVLT-Re total immediate

35

22.2 (5.4)

 HVLT-R delayed

35

6.7 (3.7)

 HVLT-R recognition discrimination

35

9.4 (2.3)

 Letter-number sequencing

35

9.5 (2.1)

 Verbal fluency—FAS

35

45.7 (13.0)

 Verbal fluency—animals

35

18.7 (5.8)

 Cognitive diagnosis (%)

35

Normal cognition

Cognitive impairment

  

65.7

34.3

Functional assessments

 Penn daily activities questionnaire—15

35

45.9 (10.7)

 Activities of daily living inventory

33

70.6 (10.2)

  1. aLevodopa equivalency daily dose.
  2. bUnified Parkinson disease rating scale.
  3. cDementia rating scale-2.
  4. dMontreal cognitive assessment.
  5. eHopkins verbal learning test-revised.